Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Paul G. Richardson, Alessandra Larocca et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 13
Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scalesJason Tay, Arleigh McCurdy, Ravi Vij et al.|Leukemia & lymphoma/Leukemia and lymphoma|2018Cited by 10